Cost-effectiveness of second-line treatment of advanced gastrointestinal stromal tumors with ripretinib versus sunitinib

CHEN Yong; HUANG Longzhuan; GU Hangye; CHEN Yaqing; CHEN Jisheng

doi:10.6039/j.issn.1001-0408.2025.06.12

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness of second-line treatment of advanced gastrointestinal stromal tumors with ripretinib versus sunitinib

更新时间：2025-09-25

- Cost-effectiveness of second-line treatment of advanced gastrointestinal stromal tumors with ripretinib versus sunitinib
- ZHONGGUO YAOFANG Vol. 36, Issue 6, Pages: 710-714(2025)
- 作者机构：
  
  广东药科大学附属第一医院临床药学重点专科，广州　510080
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.06.12
  CLC： R956;R979.1
- Received：04 June 2024，
  
  Revised：2025-02-13，
  
  Accepted：26 February 2025，
  
  Published：30 March 2025
- 稿件说明：
移动端阅览
陈永,黄龙转,顾航烨,等.瑞派替尼与舒尼替尼二线治疗晚期胃肠道间质瘤的经济性[J].中国药房,2025,36(06):710-714.

CHEN Yong,HUANG Longzhuan,GU Hangye,et al.Cost-effectiveness of second-line treatment of advanced gastrointestinal stromal tumors with ripretinib versus sunitinib[J].ZHONGGUO YAOFANG,2025,36(06):710-714.
陈永,黄龙转,顾航烨,等.瑞派替尼与舒尼替尼二线治疗晚期胃肠道间质瘤的经济性[J].中国药房,2025,36(06):710-714. DOI： 10.6039/j.issn.1001-0408.2025.06.12.

CHEN Yong,HUANG Longzhuan,GU Hangye,et al.Cost-effectiveness of second-line treatment of advanced gastrointestinal stromal tumors with ripretinib versus sunitinib[J].ZHONGGUO YAOFANG,2025,36(06):710-714. DOI： 10.6039/j.issn.1001-0408.2025.06.12.

摘要

目的

评估瑞派替尼与舒尼替尼作为晚期胃肠道间质瘤（GIST）患者二线治疗方案的经济性。

方法

基于INTRIGUE研究数据构建动态Markov模型，设定模型循环周期为6周，模拟患者15年的直接医疗成本和质量调整生命年（QALYs），以增量成本-效果比（ICER）为评价指标，比较ICER与意愿支付（WTP）阈值（我国2023年的3倍人均国内生产总值，268 200元/QALY）的大小；并对模型输出结果进行单因素敏感性分析和概率敏感性分析以考察模型的稳定性。

结果

瑞派替尼方案的健康获益低于舒尼替尼（1.21 QALYs vs.1.31 QALYs），但成本更高（323 401.88元 vs. 227 532.40元），为绝对劣势方案。单因素敏感性分析结果表明，瑞派替尼和舒尼替尼费用、无进展生存状态的效用值对ICER影响较大。概率敏感性分析提示研究结果较稳定，且随着WTP增加，瑞派替尼方案具有经济性的概率始终远低于舒尼替尼，并呈下降趋势。

结论

在当前我国的经济背景下，与舒尼替尼相比，瑞派替尼作为晚期GIST的二线治疗方案并不具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of ripretinib versus sunitinib as a second-line treatment option for patients with advanced gastrointestinal stromal tumors （GIST）.

METHODS

Based on the data of INTRIGUE study， a dynamic Markov model was constructed， with a cycle of 6 weeks； this model was used to simulate patients’ direct medical costs and quality-adjusted life years （QALYs） over 15 years. Using the incremental cost-effectiveness ratio （ICER） as the evaluation metric， a comparison was made between the ICER and the willingness-to-pay （WTP） threshold （3 times the per capita gross domestic product， which amounts to 268 200 yuan/QALY）. One-way sensitivity analyses and probabilistic sensitivity analyses were performed on the model outputs to examine the stability of the model.

RESULTS

The health benefits of ripretinib were lower than those of sunitinib （1.21 QALYs vs. 1.31 QALYs）. Still， the costs were higher （323 401.88 yuan vs. 227 532.40 yuan）， making it an inferior regimen. The results of the one-way sensitivity analysis suggested that the cost of ripretinib and sunitinib， and the health utility value in progression-free survival status had a greater impact on the ICER of the model. Probabilistic sensitivity analysis suggested that the results of the study were stable， and the probability of the cost-effectiveness advantage of ripretinib was always much lower than that of sunitinib with the increase of WTP threshold， and showed a decreasing trend.

CONCLUSIONS

In the current economic context of China， ripretinib does not have a cost-effectiveness advantage over sunitinib as a second-line treatment for advanced GIST.

关键词

Keywords

references

AL-SHARE B ， ALLOGHBI A ， AL HALLAK M N ， et al . Gastrointestinal stromal tumor：a review of current and emerging therapies [J ] . Cancer Metastasis Rev ， 2021 ， 40 （ 2 ）： 625 - 641 .

JUDSON I ， DEMETRI G . Advances in the treatment of gastrointestinal stromal tumours [J ] . Ann Oncol ， 2007 ， 18 （ Suppl.10 ）： x20 - x24 .

HUANG S Q ， LIU X ， GUO X D ， et al . Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced gastrointestinal stromal tumors：a real-world multi-center study [J ] . Transl Oncol ， 2023 ， 30 ： 101641 .

BLAY J Y ， SERRANO C ， HEINRICH M C ， et al . Ripretinib in patients with advanced gastrointestinal stromal tumours（INVICTUS）：a double-blind，randomised，placebo-controlled，phase 3 trial [J ] . Lancet Oncol ， 2020 ， 21 （ 7 ）： 923 - 934 .

BAUER S ， JONES R L ， BLAY J Y ， et al . Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib（INTRIGUE）：a randomized，open-label，phase Ⅲ trial [J ] . J Clin Oncol ， 2022 ， 40 （ 34 ）： 3918 - 3928 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）胃肠间质瘤诊疗指南2023 [M ] . 北京：人民卫生出版社， 2023 ： 55 .

The Guidelines Working Committee of Chinese Society of Clinical Oncology . Guidelines for diagnosis and treatment of Chinese Society of Clinical Oncology （CSCO） 2023 [M ] . Beijing ： People’s Health Publishing House ， 2023 ： 55 .

ZHAO J J ， SYN N L ， TAN B K J ， et al . KM subtraction：reconstruction of unreported subgroup survival data utili-zing published Kaplan-Meier survival curves [J ] . BMC Med Res Methodol ， 2022 ， 22 （ 1 ）： 93 .

YANG J P ， HAN J Q ， ZHANG Y L ， et al . Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer [J ] . Front Pharmacol ， 2022 ， 13 ： 924126 .

周挺，马爱霞 . 生存分析在药物经济学评价Markov模型转移概率计算中的应用 [J ] . 中国循证医学杂志， 2018 ， 18 （ 10 ）： 1129 - 1134 .

ZHOU T ， MA A X . The survival analysis applied in calculation of Markov model transition probability in pharmaceutical evaluation [J ] . Chin J Evid Based Med ， 2018 ， 18 （ 10 ）： 1129 - 1134 .

朱建波，王江峰，吕良忠 . 呋喹替尼与瑞戈非尼作为转移性结直肠癌三线治疗的成本-效用分析 [J ] . 药物流行病学杂志， 2022 ， 31 （ 3 ）： 173 - 177 .

ZHU J B ， WANG J F ， LYU L Z . Cost-utility analysis of fruquintinib versus regorafenib as third-line treatment for metastatic colorectal cancer [J ] . Chin J Pharmacoepidemiol ， 2022 ， 31 （ 3 ）： 173 - 177 .

POOLE C D ， CONNOLLY M P ， CHANG J ， et al . Health utility of patients with advanced gastrointestinal stromal tumors（GIST）after failure of imatinib and sunitinib：fin-dings from GRID，a randomized，double-blind，placebo-controlled phase Ⅲ study of regorafenib versus placebo [J ] . Gastric Cancer ， 2015 ， 18 （ 3 ）： 627 - 634 .

王凯旋，李顺平，窦蕾，等 . 帕博利珠单抗一线治疗不可切除或转移性MSI-H/dMMR结直肠癌的成本效果分析 [J ] . 中国新药与临床杂志， 2024 ， 43 （ 3 ）： 229 - 235 .

WANG K X ， LI S P ， DOU L ， et al . Cost-effectiveness analysis of pembrolizumab as first-line treatment for unresectable or metastatic MSI-H/dMMR colorectal cancer [J ] . Chin J New Drugs Clin Remedies ， 2024 ， 43 （ 3 ）： 229 - 235 .

蒋媛，高振宇，王美飒，等 . 赛沃替尼治疗间质-上皮细胞转化因子突变的局部晚期或转移性非小细胞肺癌的成本-效果分析 [J ] . 中国医院药学杂志， 2024 ， 44 （ 6 ）： 690 - 695 .

JIANG Y ， GAO Z Y ， WANG M S ， et al . Cost-effectiveness analysis of savolitinib for locally advanced or metastatic non-small-cell lung cancer with MET mutations [J ] . Chin J Hosp Pharm ， 2024 ， 44 （ 6 ）： 690 - 695 .

杨雷，王凤玲，黄玲，等 . 恩扎卢胺治疗转移性前列腺癌的成本-效果分析 [J ] . 药物流行病学杂志， 2024 ， 33 （ 3 ）： 269 - 276 .

YANG L ， WANG F L ， HUANG L ， et al . Cost-effectiveness analysis of enzalutamide in the treatment of metastatic prostate cancer [J ] . Chin J Pharmacoepidemiol ， 2024 ， 33 （ 3 ）： 269 - 276 .

WANG Y ， WANG H ， YI M M ， et al . Cost-effectiveness of lenvatinib plus pembrolizumab or everolimus as first-line treatment of advanced renal cell carcinoma [J ] . Front Oncol ， 2022 ， 12 ： 853901 .

赵曦，闫茜，李宁，等 . 阿贝西利联合氟维司群二线治疗HR+/HER2－晚期乳腺癌的成本-效果分析 [J ] . 药物流行病学杂志， 2023 ， 32 （ 11 ）： 1259 - 1266 .

ZHAO X ， YAN Q ， LI N ， et al . Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment for HR+/HER2－ advanced breast cancer [J ] . Chin J Pharmacoepidemiol ， 2023 ， 32 （ 11 ）： 1259 - 1266 .

MCCABE C ， PAULDEN M ， AWOTWE I ， et al . One-way sensitivity analysis for probabilistic cost-effectiveness analysis：conditional expected incremental net benefit [J ] . Pharmacoeconomics ， 2020 ， 38 （ 2 ）： 135 - 141 .

ANTONESCU C R ， BESMER P ， GUO T H ， et al . Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J ] . Clin Cancer Res ， 2005 ， 11 （ 11 ）： 4182 - 4190 .

WARDELMANN E ， THOMAS N ， MERKELBACH-BRUSE S ， et al . Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations [J ] . Lancet Oncol ， 2005 ， 6 （ 4 ）： 249 - 251 .

DEMETRI G D ， VAN OOSTEROM A T ， GARRETT C R ， et al . Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib：a randomised controlled trial [J ] . Lancet ， 2006 ， 368 （ 9544 ）： 1329 - 1338 .

HEINRICH M C ， JONES R L ， GEORGE S ， et al . Ripretinib versus sunitinib in gastrointestinal stromal tumor：ctDNA biomarker analysis of the phase 3 INTRIGUE trial [J ] . Nat Med ， 2024 ， 30 （ 2 ）： 498 - 506 .

NCCN Clinical Practice Guidelines in Oncology . Gastrointestinal stromal tumors [EB/OL ] .（ 2023-03-13 ）[ 2024-03-15 ] . https：//www.nccn.org/guidelines/category_1 https://www.nccn.org/guidelines/category_1 .

LIAO W T ， XU H Q ， HUTTON D ， et al . Cost-effectiveness analysis of fourth- or further-line ripretinib in advanced gastrointestinal stromal tumors [J ] . Front Oncol ， 2021 ， 11 ： 692005 .

FENG M Y ， YANG Y ， LIAO W T ， et al . Cost-effectiveness analysis of tyrosine kinase inhibitors in gastrointestinal stromal tumor：a systematic review [J ] . Front Public Health ， 2022 ， 9 ： 768765 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of multiple sequential treatment regimens for HER-2 positive advanced gastric cancer

Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer

Pharmacoeconomic evaluation of trastuzumab deruxtecan versus chemotherapy in the second-line treatment of advanced breast cancer with HER-2 low expression

Cost-utility analysis of tislelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

Cost-utility Analysis of Pembrolizumab in the Second-line Treatment of Advanced Hepatocellular Carcinoma Based on Two Models

Related Author

HU Xia

GUAN Xin

LIU Nana

GAO Qian

HU Dongxue

ZHENG Ying

HU Shiyuan

WANG Danfeng

Related Institution

School of International Pharmaceutical Business， China Pharmaceutical University

School of Pharmacy， Hebei Medical University

Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University

Dept. of Pharmacy， Hebei Children’s Hospital

Dept. of Clinical Pharmacology， the Fourth Hospital of Hebei Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰